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Atypical forms of diabetes mellitus in Africans 
and other non-European ethnic populations in 
low- and middle-income countries: a systematic 
literature review
Background Atypical presentations of diabetes mellitus (DM) have been 
reported in non-European ethnic populations under various names. It is 
unclear whether those names are used for the same or different clinical 
phenotypes. Unclear terminology may lead to inappropriate treatment and 
an underestimation of the burden caused by atypical diabetes phenotypes 
overlapping with classic types of diabetes. This review aimed to describe 
the terms used for atypical forms of diabetes and to investigate whether 
the terms are used for similar or different phenotypes.
Methods PubMed and Scopus were searched for relevant publications in 
French or English available before 15 September 2015 using the terms: 
”Atypical diabetes”, “Malnutrition Related Diabetes Mellitus (MRDM)”, “Fi-
bro-calculus pancreatic diabetes (FCPD)”, Protein deficient Pancreatic Dia-
betes (PDPD)”, “African diabetes”, “Ketosis prone-type 2 diabetes”, “tropical 
diabetes”, “Flatbush diabetes”, “J-type diabetes”. Titles, abstracts screening 
and quality assessment were performed by two independent authors. Ob-
servational studies addressing atypical diabetes in humans aged 14 years 
and above were included. One author extracted data from selected articles.
Results 22 articles among 350 identified articles were retained for data ex-
traction. Two atypical diabetes phenotypes were identified, each of them 
with a variety of names but similar definitions. One phenotype occurred 
in very thin people less than 30 years of age, typically from poor socio-eco-
nomic backgrounds and requires insulin for life. It differs from type 1 dia-
betes in the tolerance of high blood glucose without ketosis in the absence 
of exogenous insulin. The second phenotype resembles type1 diabetes as it 
presents with ketosis at onset but responds well, as type2 diabetes, to oral 
hypoglycemic drugs after initial stabilization with insulin. It occurs in in-
dividuals who are usually over 30 years of age, with normal or overweight 
and absence of auto antibodies mainly found in type 1 diabetes.
Conclusion The scarce existing literature used various terms for similar 
diabetes phenotypes. Agreement on nomenclature for the various forms of 
diabetes using the above reported characteristics are needed in populations 
where atypical forms of diabetes exist as well as better characterization of 
phenotypes and genotypes to inform evidence based treatment.
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Diabetes mellitus is a highly heterogeneous disease, the classification of which 
has changed as knowledge about its clinical and pathophysiological features 
have evolved [1-5]. In 1979, the National Diabetes Data Group (NDDG) es-
tablished a classification based mainly on diabetes treatment requirements [1]. 
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This classification included insulin dependent diabetes mellitus (IDDM), non-insulin dependent diabetes 
mellitus (NIDDM), gestational diabetes and diabetes secondary to other diseases like pancreatic cancer 
and other endocrine diseases [1]. In 1985, the World Health Organization (WHO) Study Group on Dia-
betes adopted the NDDG classification and malnutrition related diabetes mellitus (MRDM) was officially 
recognized [2]. MRDM was ranked as a standalone clinical subgroup with 2 subtypes, protein deficiency 
pancreatic diabetes (PDPD) and fibrocalculous pancreatic diabetes (FCPD), defined as diabetes onset in 
young people (less than 30 years of age) in developing countries, with a history of under nutrition, wasting 
and presence of pancreatic calculi or fibrosis in the FCPD [2]. However MRDM was subsequently dropped 
from official classifications as a consequence of lack of evidence by the International Expert Committee 
which revised the NDDG and WHO Study Group’s diabetes classification by introducing new nomencla-
ture and modifications based on the etiology of diabetes [3]. This modified classification includes type 
1 diabetes mellitus mainly due to auto-immune destruction of beta cells in the pancreas; type 2 diabetes 
whose etiology is essentially insulin resistance, gestational diabetes and secondary diabetes. Nevertheless, 
there are many forms of atypical diabetes which do not fit into the definition of these classic recognized 
types of diabetes. The picture is further complicated by the fact that there is no standardized nomencla-
ture in the literature to describe atypical diabetes.
Since the early 1990s, the term atypical diabetes mellitus has been used to refer to some rare types of di-
abetes mellitus such as Maturity Onset Diabetes of the Young (MODY) [6]. MODY is a well-established 
entity characterized by an autosomal-dominant transmission, onset at a young age (below 40 years old), 
a strong family history of diabetes, slow progression, mild or absence of clinical symptoms or signs of 
diabetes and response to oral anti-diabetic treatment [7]. This form of diabetes resembles classic type 2 
diabetes but differs in having a young age of onset and differs from type 1 diabetes by its slow onset, si-
lent clinical manifestation, response to oral therapy and absence of islet auto-antibodies [7]. Latent Auto-
immune Diabetes of Adult (LADA), also referred to as type 1.5 diabetes, is another atypical form, which 
resembles type 1 diabetes but with a late age of onset [8]. LADA may be mistakenly diagnosed as type 2 
diabetes based on its clinical manifestation; however it differs from type 2 diabetes because of the pres-
ence of auto antibodies such as glutamic acid decarboxylase antibodies (anti-GAD) which are absent in 
type 2 diabetes [8].
LADA and MODY are well characterized and have long been recognized globally as atypical forms of di-
abetes. There are, however, other forms of atypical diabetes which do not clearly fit within the existing 
classifications. These forms appear to be more prevalent in populations of African and Asian ancestry. 
One such rare and atypical presentation of diabetes mellitus known as ketosis prone type 2 diabetes, has 
been described in people of non-white ancestry in European and American countries [9-12]. However, 
the scarcity of data on this form of diabetes from low and middle income countries (LMIC) makes it dif-
ficult to assess the prevalence of these forms of diabetes and to plan appropriate health services.
Terms such as “atypical diabetes”, “Malnutrition Related Diabetes Mellitus (MRDM)”, “Fibro-calculus 
pancreatic diabetes (FCPD)”, Protein deficient Pancreatic Diabetes (PDPD)”, “African diabetes”, “Ketosis 
prone-type 2 diabetes”, “tropical diabetes”, “Flatbush diabetes”, “J-type diabetes” among others have been 
used to describe diabetes phenotypes which do not clearly fit the type1 or type 2 diabetes definitions and 
which are not yet well understood. These terms are not, however, clearly defined in the literature, and it 
is unclear whether the same term is used to describe different phenotypes in different contexts or con-
versely, whether different terms are used to describe similar phenotypes in different contexts. This lack of 
clarity is problematic because it may lead to inappropriate diabetes classification at diagnosis, difficulties 
in the application of diabetes treatment guidelines (based on classic types of diabetes) and the provision 
of appropriate educational materials globally and particularly in underserved settings.
The aim of this study, whose protocol has been published in PROSPERO [13] is to systematically review 
available evidence on different terms used for atypical diabetes in order to clarify if they have the same or 
different definitions and to assess whether distinct phenotype(s) can be identified.
METHODS
Search strategy
PubMed and Scopus databases were searched to retrieve relevant publications related to the review ob-
jectives. The following key words were used to search relevant articles: Flatbush diabetes, ketosis-prone 
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diabetes, tropical diabetes, malnutrition-related diabetes, fibrocalculous pancreatic diabetes, chronic pan-
creatic diabetes, protein deficiency pancreatic diabetes and African diabetes. The search strategy was ad-
justed as appropriate for each database. The search strategy is detailed in the Annexes S1 and S2 in Online 
Supplementary Document. References and citations of included studies were screened by one author 
(CB) to identify relevant documents.
Inclusion and exclusion criteria
Observational studies including prospective or retrospective cohort studies, case–control, cross-sectional 
studies and case series published before the date of download (15 September 2015) on human non-Eu-
ropean ethnic participants aged 14 years and above were included. We included studies in English or 
French reporting on atypical diabetes mellitus expressed as used key words. Studies with unavailable ab-
stract, genetic studies, case reports and studies focusing on classic types of diabetes such as type 1 and type 
2 diabetes mellitus, gestational diabetes mellitus, secondary diabetes, LADA and MODY were excluded.
Selection and critical appraisal of studies
Titles and abstracts of retrieved bibliographic records were screened by two different authors (CB and 
DS). Disagreements were resolved by discussion among the two and consensus. The full text of each po-
tentially eligible study was retrieved through HINARI and the library of Edinburgh University. Full texts 
were critically appraised independently by two authors (CB and DS). The quality of individual studies 
was assessed using the Health Evidence Bulletins – Wales checklist for assessing the quality of observa-
tional studies [14]. This tool was chosen because it can be used to assess different types of observational 
studies. Articles were retained, for data extraction, based on relevance to the review’s objectives, represen-
tative sample size to answer the research question and clear objectives and outcomes.
Data extraction and report synthesis
Data extraction was done by one author (CB) using a specially designed worksheet including terms used 
to describe atypical forms of diabetes, its definitions clinical and biochemical characteristic. Study char-
acteristics including date of publication, country and study method (sample size, type of study, setting) 
were extracted from individual studies. Terms identified that used the same definition and similar clin-
ical characteristics were grouped in one phenotype. Narrative report was done by CB and reviewed by 
SM, ID, RM and SW.
RESULTS
Overview of included articles
A total of 282 articles from PubMed and 68 from Scopus were identified. Figure 1 describes the selection 
process. Following removal of duplicates there were 338 articles of which 55 were retained for quality 
assessment after titles and abstract screening against inclusion criteria and confirming relevance to the 
review objectives. Quality assessment led to the rejection of a further 35 articles and 20 were retained for 
data extraction and narrative synthesis with a further two studies identified from references. The main 
reasons for exclusion of full text at appraisal stage were high risk of bias, inappropriate study population 
in terms of sample size and participants’ selection, unclear objectives and outcomes and lack of definition 
of atypical diabetes terminology. The final number of articles remaining for analysis was 22.
Most of the articles included (12 out of the 22) were published before 2000 as shown in Table 1. The 
majority of studies were from various Asian countries (13 among 22 included records) mainly from In-
dia. There was a scarcity of data from African countries, Latin America and the Caribbean; there were 
three clinic-based studies with a small sample sizes from Ethiopia and three from Jamaica using differ-
ent terms for atypical diabetes, with small sample size and different populations. One study from Ethio-
pia was included even though it did not have the definition of any form of atypical presentation but did 
contribute data on the clinical characteristics of a young sub-Saharan population with diabetes requiring 
insulin [30]. All studies included participants with diagnosed diabetes; however there was considerable 
heterogeneity in the age groups of study participants. Some studies included participants aged 35 years 
or less [18,19,23,24], while others included participants of all ages. In addition, the included studies had 
a variety of objectives and outcomes that made comparison difficult. Nevertheless, the included studies 
addressed various presentation of diabetes which might help to clarify the different terms used for atypi-
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cal presentation of diabetes and to define a phenotype or phenotypes associated with these terms. Table 
1 provides a summary of the characteristics of the included articles.
Names and definitions of atypical forms of diabetes from the literature
In 1983, Mohan and collaborators used the term “tropical pancreatic diabetes (TPD)” for diabetes mellitus 
occurring in individuals aged 15 to 30 years who were underweight or wasted and required insulin but 
who did not experience ketosis on discontinuation of insulin treatment; this phenotype is also referred 
to as ketosis resistant diabetes [15]. In subsequent years, the same author and other scientists added new 
criteria to the definition of TPD: history of chronic abdominal pain from childhood, absence of potential 
causes of pancreatic calcification such as alcohol consumption, gall stones and other biliary obstructive 
diseases or high parathyroid hormones; and presence of pancreatic calcification on plain abdominal ra-
diography [16,17]. Subsequently, other authors have used different terms for a similar phenotype: cal-
cific tropical pancreatic diabetes (CTPD) with addition of symptoms or signs of under nutrition [18], fi-
bro-calculus pancreatic diabetes (FCPD) with an addition of fibrosis and biliary duct dilatation identified 
on abdominal ultrasound [19,23,24,26].
The above phenotype under various terminologies was described in some studies as a subclass of malnu-
trition related diabetes (MRDM), the term recommended by WHO in 1985 [19,23,24]. However, in one 
report, MRDM was used with a global definition including diabetes in individuals with poor socioeco-
nomic status associated with one or more of the following: at least 3 months duration of typical symptoms 
of diabetes, leanness with underweight (BMI≤18.5 kg/m2) at diabetes onset, insulin requirement from 
diagnosis for blood glucose control and absence of significant ketonuria [20]. MRDM has been reported 
to also cover protein deficient pancreatic diabetes (PDPD) with a similar definition [19]; and with the ad-
dition of diabetes onset below the age of 30 years, lower age of onset of “TPD” and severe hyperglycemia 
usually greater than 11.2 mmol/dL in other studies [23,24]. Different names such as “J type diabetes”, 
phasic insulin dependent diabetes mellitus (PIDDM) and ketosis resistant diabetes have been used in dif-
ferent studies for phenotypes similar to PDPD with an additional criterion of high daily insulin require-
ment which may denote insulin resistance [16,21,22,25].
Figure 1. Flowchart showing inclusion process.
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Table 1. Characteristics of included studies sorted by date of publication




countrY studY design sample size
Mohan [15] 1983 India case-control study control +23, NIDDM: 42, IDDM: 40, TPD: 42
Mohan [16] 1985 South India case-control, clinic based
33 TPD; 35 type 2 (NIDDM); 35 non diabetic; all matched for 
age, sex, duration of diabetes; consecutive inclusion on 2 y
Mohan [17] 1985 South India Case-control, hospital based 20 TPD, 20 IDDM, 20 MODY age and sex matched
Vannasaeng [18] 1986 Thailand case-control, clinic based
13 CTPD, 23 IDDM, 18 NIDDM and 10 non-obese individual 
without diabetes
Ramachandran [19] 1987 South India cross-sectional, hospital based
545 patients with diabetes (461 included, 80 unclassified and 
4 GD excluded)
J. Abdulkadir [20] 1990 Ethiopia
cross-sectional and case-control, 
clinic based
63 MRDM, 18 type1, 19 type 2 ; 6 MRDM were excluded in hor-
mones work up because not fitting MRDM definition
Ragoobirsingh [21] 1990 Jamaica case-control study 13 PIDDM, 11 IDDM, 10 NIDDM and 12 normal subject
Morrison [22] 1992 Jamaica case-control clinic base study 14 PIDDM, 10 IDDM, 10 NIDDM; 10 normal control
Bhatia [23] 1995 North India case-control, clinic based
20 consecutive FCPD, 19 PDPD, 20 Patients with TYPE 1 DM, 
32 healthy
Dabadghao [24] 1996 North India case-control clinic base 23 PDPD, 25 FCPD, 62 type 1
Ragoobirsingh [25] 1997 Jamaica case-control 14 PIDDM, 10 IDDM, 10 NIDDM and 10 healthy controls
Mohan [26] 1998 South India case-control study
57 FCPD, 40 Type 1 DM, 71 Type 2 DM, 45 healthy non  
diabetic patients
Mauvais-Jarvis [12] 2004 France cohort study
111 Sub-Saharan origin individuals with ketosis-prone type 2 
diabetes, 21 with type 1 diabetes and 88 with type 2 diabetes
Maldonado [27] 2005 USA
cohort study, tertiary hospital 
based study
106 patients with ketosis-prone diabetes
Otiniano [28] 2005 USA cross-sectional
172 patients set in 2 groups: 1 group with metabolic syndrome 
as par WHO definition and 1 group with metabolic syndrome
Balasubramanyam [29] 2006 USA
longitudinal case-control 
study(31month follow up)
294 patients with DKA, all ages and gender
Fekadu S [30] 2010 Ethiopia
case-control clinic base(Multi 
center clinic based)
107 patients 110 controls
Liu [31] 2013 Chine case-control clinic based study
159 overall patients from which 79 with ketosis onset diabe-
tes and 80 KPD
Seok [32] 2013 Korea
3 tertiary centers based Cohort 
study (4years follow up)
60 newly diagnosed KPD
Gupta [33] 2014 Thailand case-control 20KPD, 12 type 1 DM
Yotsapon [34] 2014 Thailand
cohort study, 24months follow 
up clinic based
20 KPD and 12 type 1 DM
Zhang [35] 2015 China cross-sectional study 238 individuals with diabetes from inpatients department
NIDDM – non-insulin dependent diabetes mellitus, IDDM – insulin dependent diabetes mellitus, TPD – tropical pancreatic diabetes, MODY – maturi-
ty onset diabetes of the young, CTPD – calcific tropical pancreatic diabetes, GD – gestational diabetes, MRDM – malnutrition-related diabetes mellitus, 
FCPD – fibro-calculous pancreatic diabetes, PDPD – protein deficient pancreatic diabetes, DKA – diabetic ketoacidosis, KPD – ketosis-prone diabetes, 
PIDDM – phasic insulin dependent diabetes mellitus
Ketosis prone diabetes (KPD) has been defined as a subgroup of TPD with the addition of increased 
susceptibility to developing ketosis [16]. However KPD has been used in other studies of residents and 
emigrants from LMIC to denote newly diagnosed diabetes, usually after the age of 30 years of age, with 
symptoms and signs of diabetes, unprovoked ketosis (absence of provoking factor for ketosis such as in-
fection), transient insulin requirement and absence of islet cells (ICAs Ab) and glutamic acid decarboxy-
lase anti-bodies (GADAb) [12,29,32,34,35]. This phenotype is variously described as ketosis prone dia-
betes [28,31,33] or ketosis prone type 2 diabetes [12]. These names have been used interchangeably in 
the same article by some authors [27]. Flatbush diabetes, atypical diabetes and type 1.5 diabetes were 
also reported as synonyms for ketosis prone diabetes or ketosis prone type 2 diabetes [35]. Furthermore, 
subgroups of patients presenting with ketosis have been defined: ketosis prone diabetes type 1a which is 
defined as equivalent to classic diabetes type 1a characterized by autoimmune destruction of beta cells in 
the pancreas, ketosis prone type 1b defined as diabetes with non autoimmune beta cells function failure, 
ketosis prone type 2a and ketosis prone type 2b respectively characterized by preserved beta cell function 
and with presence of autoantibodies in the type 2a and without antibodies in type 2b [29]. In another 
study, subgroups of KPD were defined using different names, such as KPDM-insulin in which diabetes 
could be controlled after discontinuing insulin and using alternative treatments and KPDM+insulin char-
acterized by insulin requirement for life in order to manage hyperglycaemia [33].
Bavuma et al.










Phenotypes and clinical profile
From the above definitions numerous names were used for similar phenotypes which could collectively 
be described as either malnutrition related diabetes (MRDM) or ketosis prone diabetes whose character-
istics are summarized in Table 2.
MRDM has been described under the following names: “tropical pancreatic diabetes”, “chronic tropical 
pancreatic diabetes”, “fibro-calculus pancreatic diabetes”, “protein deficient pancreatic diabetes”, “J type 
diabetes” and “phasic insulin dependent diabetes (PIDDM)”. Most of these publications were before 2000, 
apart from some papers from Ethiopia describing atypical presentation of insulin requiring diabetes [30]. 
The common characteristics of this phenotype are the occurrence of diabetes in abnormally lean young 
people from poor socioeconomic conditions; with “type 1 like” diabetes at presentation but without ke-
toacidosis and the potential for some people to manage hyperglycaemia after the acute phase in which 
insulin requirements are high with non-insulin treatments.
The only study identified describing the prevalence of MRDM estimated that it occurred in 6% of Indian 
diabetic patients ≤30 years old [19]. The age of onset was typically found to be within the third decade of 
life, which is the between median age of onset of type 1 diabetes and that of type 2 DM [19,20,23,24,26]. 
For example in one study, the mean (± standard deviation) age at onset was 23.6 ± 4.4 years in this pheno-
type (MRDM) while it was 14.5 ± 7.6 in type 1 DM [24]. As most of the studies included participants aged 
30 years or less and thereby excluded those who had their diabetes diagnosed after that age, the preva-
lence of MRDM may be underestimated. Fekadu and collaborators in Ethiopia found a male preponder-
ance and poor socioeconomic conditions in their insulin requiring patients in their study of the atypical 
diabetes phenotypes [30]. The atypical presentation of diabetes, in abnormally thin people, appeared to 
be also characterized by lower body mass index at onset of diabetes in comparison to other classic types 
of diabetes [18,19,26], features of chronic malnutrition such as disproportionate skeletal growth, parotid 
enlargement, skin changes and/or scalp hair changes [20,30]. However Ramachandran and co-authors 
found low BMI in both people with type 1 and with atypical diabetes without other features of malnutri-
tion related diabetes in their study, which was conducted in an urban tertiary level health facility in India. 
Presumably, this difference might relate to differences between populations in prevalence of malnutrition 
Table 2. Identified phenotypes’ characteristics and classic types of diabetes
characteristic mrdm tYpe1 dm Ketosis-prone tYpe 2 dm tYpe 2 dm
Subtypes PDPD FCPD
Onset age
Third decade or 
early adulthood 
(≤30 y)
Fourth decade or 
early adulthood 
(≤40 y)
Mostly less than 
18 y
Third and fourth decade
Majority in fourth 
decade
Family history of diabetes Weak* Weak* Moderate† Strong‡ Strong‡
History of childhood  
malnutrition
Strong§ Strong§ - - -
Body mass index  
(5kg/m2)
Low (<18.5) Low (<18.5)
Normal  
(18.5-24.9)




Hyperglycemia at diagnosis Severe Severe Moderate Severe Moderate
Chronic abdominal pain No Yes No No No
Ketosis in urine in absence 
of insulin treatment
Absent Absent
Present, often with 
triggering factor










Requiring insulin at onset 
and responding to oral ther-
apy after one to two years
Non-insulin  
dependent
Calcification, bile duct  
dilation or decreased size of 
pancreas on imaging
Absent Present Absent Absent Absent
Beta cell function Impaired Impaired Impaired
Reserved with improvement 





Exocrine pancreatic  
deficiency
Rare Frequent Absent Absent Absent
PDPD – protein deficient pancreatic diabetes, MRDM – malnutrition-related diabetes mellitus, DM – diabetes mellitus, FCPD – fibro-calculous pan-
creatic diabetes, y – years
*No association with family history of diabetes, sporadic case.
†Moderate association with family history of diabetes, often first degree family members are affected [36].
‡Strong association with family history of diabetes.
§Strong association with a history of childhood malnutrition.
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and/or differences in research settings (tertiary vs primary health facilities). Other characteristics report-
ed by one or two studies, were the requirement of high daily insulin dose to control blood glucose [23] 
and lack of family history of diabetes [19].
MRDM, as described in 1985 by the WHO, had two sub-types: protein deficient pancreatic diabetes 
(PDPD) and fibrocalculus pancreatic diabetes, with the latter characterized by impairment of exocrine 
pancreas and changes on pancreas imaging such as calcification in the pancreas or fibrosis, biliary duct 
dilatation and decreased size and irregular surface of the pancreas [17,22,23]. Very few studies with small 
sample sizes evaluated the secretion of insulin by beta cell function in this MRDM phenotype and report-
ed a better beta cell function than in classic type 1 but lower than in type 2 DM [15,16,18,19,23]. How-
ever a report from Ethiopia recorded similar beta cell function in this phenotype and type1 diabetes with 
lower beta cell function than in type 2 diabetes. Antibodies were reported to be rare in this phenotype in 
one clinic-based study without a comparator group [24].
Key features of MRDM phenotype described above are in line with the1985 WHO definition: onset be-
low the age of 30 years, living in poverty, lack of ketosis in presence of very high blood glucose, low BMI, 
relative presence of features of under nutrition, requirement of high dose of insulin to control blood glu-
cose, relative beta cell impairment with fibrocalcific pancreatic changes in a subset of patients.
In contrast, ketosis prone diabetes differs from MRDM in age at onset, higher BMI and presence of keto-
sis at onset. The age at diagnosis of KPD is reported to be later (in 4th decade) compared to that in type 
1 DM [9,20,26] whose onset is typically around first and second decade. Family history of diabetes and 
male preponderance have been found to be frequent in this phenotype as well as higher body mass index 
than that in type 1 but similar to that in classic type 2 Diabetes [12,29,35]. The onset of this phenotype 
is accompanied by ketosis without provoking factors and insulin discontinuation for other treatment op-
tions across the time of follow up (3 to 12 months from onset) [32]. Permanent insulin treatment was 
recorded in a set of patients with this phenotype and those patients were characterized by impaired beta 
cell function [12]. Patients with older age at onset, higher level of endogenous insulin and metabolic syn-
drome were more likely to be able to switch from insulin to other treatments for diabetes [27,28], in two 
studies on multiethnic groups in USA without comparators from elsewhere. Furthermore, patients with 
KPD are described as having beta cell function reserve between that of classic type 1 and type 2 as ex-
pressed by both fasting and stimulated C peptide levels [31-35].
DISCUSSION
This systematic review identified heterogeneous studies describing characteristics of people with atypical 
diabetes. Two main phenotypes have been identified that have been described using a variety of names. 
The first phenotype that we have identified as MRDM has some similar characteristics to the type 1 di-
abetes. It occurs in lean people living in poor socioeconomic conditions whose diagnosis is made at an 
older age (third decade) than most people with type 1 diabetes, who have features of under nutrition, 
absence of beta cell antibodies, who may have pancreatic calcification on imaging and who do not devel-
op ketosis. Characteristics of MRDM have been reported mainly by a few historical clinic based studies 
with small sample sizes from LMIC with noticeable scarcity of data from Africa. The second phenotype, 
KPT2DM typically occurs in normal weight or overweight people who present with unprovoked ketosis 
at onset but in whom insulin may be withdrawn and replaced with other diabetes treatments after some 
months of glucose stabilization and has been reported to occur in Asian countries and in people of Afri-
can ancestry in developed countries.
There is a scarcity of contemporary data on prevalence of MRDM. The existing literature from clinics based 
research in urban tertiary settings suggests that it is rare [19]. For example no cases of this phenotype were 
observed in 550 patients seen at Yaoundé central hospital in Cameroon [37]. However prevalence would 
be expected to be higher in underserved rural populations. Most qualified health professionals who might 
generate research questions and lead research projects are located in urban settings and have high clini-
cal workloads, with limited opportunity and funding for conducting research. In addition, diabetes and 
non-communicable diseases in general suffer from persistent inequities in global health research funding, 
which continues to favor infectious diseases. Against this background, it is conceivable that cases of MRDM 
in rural clinics might be misclassified as classic type 1 diabetes. The implications for patients are signifi-
cant, if such misclassification results in inappropriate treatment based on guidelines for type 1 diabetes.
In order to ensure that appropriate treatment guidelines are being followed and to build responsive and 
appropriate health systems, it is important to understand the contribution of different types of diabetes 
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to a nation‘s overall diabetes burden. The situation is particularly challenging for health system planners 
in rapidly developing low- and middle-income countries (LMIC), who are already grappling with an in-
creasing prevalence of type 2 diabetes, driven by a substantial increase in the prevalence of obesity and 
sedentary lifestyles.
MRDM typically occurs in the 3rd decade of life, which is older than the age at which type 1 diabetes typ-
ically occurs. Childhood under nutrition might be one of the reasons why diabetes mellitus is increasing 
in the young population in LMIC. For example Shen and collaborators reported that pre-diabetes and 
diabetes were common in young, lean South Asians in a multi-center population based study [38]. Fur-
thermore, a case-control study from Jamaica showed that beta cell impairment and insulin sensitivity in 
adults with a history of under-nutrition varied by type of malnutrition and was worse in adults with a 
history of marasmus than those with a history of kwashiorkor [39].
Low body mass index (BMI) at onset was recorded to be frequent in MRDM and considered as a criteri-
on for MRDM diagnosis by some studies. However one study recorded that body mass index was simi-
lar in people diagnosed with MRDM and classic type 1 DM. This discrepancy might be due to different 
study populations at different stage of disease at diagnosis and underlying BMI distributions in popula-
tions. However low BMI at onset in such poor patients may be due to many factors such as long duration 
of diabetes symptoms, as MRDM patients have been recorded to tolerate high blood glucose, exocrine 
pancreatic failure with nutrient malabsorption leading to wasting or persistent malnutrition from child-
hood sustained by hunger and poverty. Although there is a relationship between low body mass index 
and MRDM, there is a need to clarify whether MRDM contributes to weight loss.
One study addressing MRDM highlighted the low binding of insulin to blood cells, which reflects insu-
lin resistance and that is consistent with longitudinal evidence which supports the correlation between 
low birth weight and cardiovascular risks including insulin resistance known to cause diabetes [40]. The 
pathophysiological mechanism of insulin resistance might be the same and may explain the high insulin 
daily dose required for blood glucose control in this phenotype but more research to confirm this hypoth-
esis is needed. Patients with this phenotype may be managed as classic type 1 with additional consider-
ation of their nutritional needs and exocrine pancreatic failure but more research is required to identify 
optimal treatments and to define the appropriateness of changing treatment.
To the best of our knowledge, only one study has described complications of the MRDM phenotype: a 
case-control study with a small sample, reported higher mean level of albuminuria in that phenotype than 
in IDDM (Type 1) and NIDDM (type2) (PIDDM: 153.1 ± 48.3; 37.7 ± 15.8 in NIDDM and 38.6 ± 15.8 in 
IDDM; P < 0.05) as well as decreased insulin binding to red and white blood cells together with lack of 
insulin in the atypical phenotype [22].
The findings are consistent with the WHO population based stepwise non-communicable disease risk 
factors survey in Rwanda which found a high prevalence of albuminuria in rural areas (with frequent 
childhood under nutrition) compared to semi-urban and urban area [41]. This suggests that patients with 
this phenotype would be at particularly high risk of developing diabetic nephropathy. However there is 
a lack of evidence on complications of diabetes in this population and the effectiveness of interventions.
Ketosis-prone type 2 diabetes includes features of both type 1 and type 2 diabetes. It resembles type 1 
DM by the presence of ketosis at diagnosis; and type 2 DM in terms of later age and association with over-
weight at onset as well as preserved insulin secretion. Ketosis-prone type 2 diabetes has been described in 
African American populations and African immigrants to Europe. However cases have also been report-
ed in European ancestry populations [42]. Very few studies from Africa have described this phenotype, 
although around 30% of patients presenting with hyperglycaemic crisis in an urban tertiary hospital in 
Cameroon were identified as having KPD [43]. In terms of the presence of antibodies and pancreatic beta 
cell function, ketosis prone type2 DM has been attributed the category of A-β+ (antibody negative and 
preserved beta cell function). This makes it different from LADA which is described as A+ β+. Despite 
many publications describing this phenotype, there is no consensus yet about whether it should be con-
sidered in current classification systems and under which name. Furthermore, existing treatment guide-
lines do not address its management and the risk of complications is not clear.
CONCLUSION
Diabetes classification has evolved continuously however its presentation is heterogeneous in LMICs 
where there is limited information available about less common forms of diabetes. The lack of consen-
sus on the naming and classification of diabetes occurring in abnormally thin young people in poor 
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socioeconomic areas may overestimate type 1 DM prevalence and may result in inappropriate man-
agement of the subset of individuals with atypical diabetes. Further translational research to character-
ize diabetes, using reported characteristics in populations living in poverty with prevalent childhood 
malnutrition, is required.
Ketosis-prone diabetes phenotype, “type 2 DM-like with unprovoked ketosis at onset”, appears to ex-
ist in association with modernization and urbanization. It is unclear whether this can be considered as 
a subtype of type 2 DM and managed accordingly. A systematic review of evidence on the pathophys-
iology of this phenotype and further studies on adequate sample size to identify potential reasons to 
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